Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
14:38:32 EST Sat 07 Feb 2026
Enter Symbol
or Name
USA
CA



Q:ATOS - ATOSSA THERAPEUTICS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
ATOS - Q1.05.17·7.400.55.34+0.010.2156.17521,9145.33  5.54  5.2119.35  4.90519:33:44Feb 0515 min RT 2¢

Recent Trades - Last 10 of 1914
Time ETExPriceChangeVolume
19:33:44Q5.450.122
19:24:48Q5.3650.0353
19:19:07Q5.42370.0937100
18:32:56Q5.450.12100
18:07:46Q5.450.121
17:59:27Q5.4440.1145
17:57:24Q5.44830.118312
17:46:55Q5.480.15100
17:44:47Q5.480.151
17:40:20Q5.560.2340

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-02-05 08:30U:ATOSNews ReleaseAtossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program
2026-01-21 09:05U:ATOSNews ReleaseAtossa Therapeutics' Founder and CEO Steven Quay, M.D., Ph.D. Named One of The Top 50 Healthcare Technology CEOs of 2025
2026-01-16 16:40U:ATOSNews ReleaseAtossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy
2026-01-06 08:15U:ATOSNews ReleaseAtossa Therapeutics Receives FDA "Study May Proceed" Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer
2025-12-17 08:15U:ATOSNews ReleaseAtossa Therapeutics Wins 2025 Clinical Trials Arena Research and Development Excellence Award in Precision Endocrine Therapy Category
2025-12-15 08:00U:ATOSNews ReleaseAtossa Therapeutics Presents Four Clinical Trial Updates Highlighting (Z)-Endoxifen Research at the 2025 San Antonio Breast Cancer Symposium
2025-12-11 08:00U:ATOSNews ReleaseAtossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for Duchenne Muscular Dystrophy
2025-12-09 08:00U:ATOSNews ReleaseAtossa Therapeutics Announces Issuance of U.S. Patent Covering Enteric Oral (Z)-Endoxifen Formulations and Methods of Treating Patients Using (Z)-Endoxifen
2025-12-04 08:00U:ATOSNews ReleaseAtossa Therapeutics Details Accelerated FDA Strategy to Advance (Z)-Endoxifen Across Breast Cancer Continuum
2025-12-02 08:00U:ATOSNews ReleaseInsilico Medicine and Atossa Therapeutics Publish AI-Driven Study in Nature Scientific Reports Identifying (Z)-Endoxifen as a Potential Therapeutic Candidate for Glioblastoma
2025-11-17 09:07U:ATOSNews ReleaseAtossa Highlights Emerging Opportunity for (Z)-Endoxifen in Duchenne Muscular Dystrophy, Including Symptomatic Female Carriers, Following Peer-Reviewed Publication and Scientific Presentation
2025-11-12 08:15U:ATOSNews ReleaseAtossa Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
2025-11-06 08:00U:ATOSNews ReleaseAtossa Therapeutics Announces Acceptance of Four Abstracts Highlighting (Z)-Endoxifen Research for Presentation at the 2025 San Antonio Breast Cancer Symposium
2025-10-21 08:00U:ATOSNews ReleaseAtossa Therapeutics Highlights Progress in RECAST(TM) DCIS Platform Trial at Early Detection Research Conference; Laura Esserman, MD, MBA, to Discuss Active-Surveillance Strategy and Novel Endocrine Agents
2025-10-15 08:00U:ATOSNews ReleaseAtossa Therapeutics to Present at the Maxim Growth Summit 2025
2025-10-14 08:00U:ATOSNews ReleaseAtossa Appoints Mark Daniel, CPA, as Chief Financial Officer to Lead Finance, Systems, and Capital Strategy for Commercial Readiness
2025-10-13 08:00U:ATOSNews ReleaseAtossa Advances Global Patent Strategy for Z-Endoxifen with New Protection in Israel and Ongoing Renewals
2025-10-06 08:00U:ATOSNews ReleaseAtossa Therapeutics Streamlines EVANGELINE Breast Cancer Clinical Trial to Prioritize for 2026 NDA-Enabling Activities
2025-10-01 08:30U:ATOSNews ReleaseAtossa Therapeutics Names Janet R. Rea, MSPH, as Senior Vice President, R&D to Accelerate (Z)-Endoxifen Toward Key Regulatory Milestones
2025-09-17 08:00U:ATOSNews ReleaseAtossa Therapeutics Appoints CORE IR for Investor Relations, Shareholder Communications and Public Relations Services